Mansoori S et al., 2021-04-26: Swedish phase 2a study of individually dose-adjusted mebendazole in 11 patients with treatment-refractory gastrointestinal cancer. All evaluable patients progressed rapidly and four met criteria for hyperprogression.
Individualized dose adjusted mebendazole is safe and well tolerated in patients with advanced cancer but all patients experienced rapid progressive disease.
n/a
Mansoori S et al., 2021-04-26: Swedish phase 2a study of individually dose-adjusted mebendazole in 11 patients with treatment-refractory gastrointestinal cancer. All evaluable patients progressed rapidly and four met criteria for hyperprogression. Study type: phase 2a, single-arm, individualized therapeutic drug monitoring. N=11 enrolled, 10 started treatment. Country: Sweden (Uppsala University). Dose: oral mebendazole adjusted up to 4 g/day to target serum concentration 300 ng/mL, 16 weeks. Funder: not stated in the abstract; authors are Repos Pharma founders. Conflicts: M.F., R.L. and P.N. co-founders of Repos Pharma AB; A.L. chairman of the board. Maker: Repos Pharma AB (ReposMBZ). Comparator: none. Results: all eight patients evaluated at 8 weeks had progressive disease; four fulfilled hyperprogression criteria; only five reached target serum concentration; no severe adverse effects.
